Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Celldex Turning Into A Compelling Immunotherapy Biotech

"Shoulda, coulda, woulda" will probably be my investing epitaph. While there is no shortage of investment advice telling you that long-term investment success is predicated on developing a consistent method of evaluating stocks and sticking to your valuation guns, the consequences can be painful

A perfect case in point is Celldex Therapeutics (NASDAQ:...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.